Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-RM2 PET/CT Versus 68Ga-PSMA-617 PET/CT in Intermediate Risk Prostate Cancer
NCT03606837Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jul 2019
- Primary completion
- Jun 2023
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-DOTA-Bombesin and 68Ga-PSMA-617 in prostate cancer (PCa), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Median Standardized Uptake Value. Started Jul 2019; status: completed.
02
Drugs
68Ga-DOTA-Bombesin68Ga-PSMA-617
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03606837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03606837.